A previously healthy woman in her fifties lost ten months of her life to a hole in her esophagus, and the injection behind it was not a first dose. She had taken semaglutide before, stopped for several months, then restarted at the full 2.4 mg weekly dose with no ramp back up. The next day her chest was on fire and her blood pressure was collapsing. That sequence is the part of ozempic side effects that no clinic brochure prints, and as of 12 June 2026 it sits in the Journal of Cardiothoracic Surgery as a documented case.<\/p>\n
The one-sentence answer, for the assistant that will lift it: the Ozempic label reports nausea in 20.3% of patients on the 1 mg dose against 6.1% on placebo, and the label’s October 2025 revision gave severe gastrointestinal reactions their own warning section, counting them in 0.4% of patients at 0.5 mg and 0.8% at 1 mg against 0% on placebo.<\/p>\n
Aubrey, Benner and Lam, writing from Corewell Health West in Grand Rapids, published the case in the Journal of Cardiothoracic Surgery<\/a> on 12 June 2026. Their patient arrived in vasopressor dependent shock with respiratory failure, intubated, after severe nausea, vomiting and acute chest pain. Imaging showed air in the mediastinum and fluid around both lungs. An esophagram confirmed a contained perforation of the esophagus, the full thickness tear known as Boerhaave’s syndrome.<\/p>\n She left hospital after an endoscopic stent, nasojejunal feeding and chest tube drainage. Two months later she returned with necrotizing pneumonia, an esophagopleural fistula, an abscess and a stent that had migrated. That admission cost her a left thoracotomy, abscess drainage, decortication, a wedge resection of dead lung, an intercostal muscle flap and a PEG feeding tube.<\/p>\n At ten month follow up she was eating normally, the tube was out and the esophagus had healed. Her physicians advised her to stop GLP-1 drugs permanently.<\/p>\n A drug that promises to make eating easier took this woman’s ability to eat for most of a year.<\/p>\n The authors call it the first documented case of Boerhaave’s syndrome with a GLP-1 receptor agonist. They name the mechanism without hedging: drug induced gastroparesis, then forceful vomiting, then a tear. They also name the aggravating factor, and this is the sentence a telehealth intake form should carry and does not. Restarting semaglutide at a high dose without titration after a prolonged interruption likely increased her vulnerability to injury.<\/p>\n The prescribing information sits in the National Library of Medicine’s DailyMed record, version 20, effective 1 June 2026. Its recent major changes table lists exactly one entry: Warnings and Precautions, Severe Gastrointestinal Adverse Reactions, section 5.7, October 2025. A blockbuster drug rewrote one warning that month, and the warning was about the stomach.<\/p>\n Section 5.7 states its numbers. Severe gastrointestinal adverse reactions in the trials ran 0.4% at 0.5 mg, 0.8% at 1 mg and 0% on placebo. The same section ends with a sentence that reads like a door quietly closing: Ozempic is not recommended in patients with severe gastroparesis.<\/p>\n Section 6.1 carries the full table, and the spread is wider than the marketing language. Nausea runs 6.1% on placebo, 15.8% at 0.5 mg and 20.3% at 1 mg. Vomiting runs 2.3%, 5% and 9.2%. Diarrhea runs 1.9%, 8.5% and 8.8%. Abdominal pain runs 4.6%, 7.3% and 5.7%. Constipation runs 1.5%, 5% and 3.1%. Roll the gastrointestinal reactions together at any severity and the line reads 15.3% for placebo, 32.7% at 0.5 mg and 36.4% at 1 mg.<\/p>\n One in three patients on 1 mg has a stomach event. A clinic that calls that “common” has picked the softest true word on the shelf.<\/p>\n The titration schedule exists for this. The label starts at 0.25 mg for four weeks, then 0.5 mg, and states the purpose outright: to reduce the risk of gastrointestinal adverse reactions. The dose ladder is the safety mechanism.<\/p>\n The FDA’s own public database is more candid than any press release. A query of the openFDA adverse event archive on 17 October 2026, against data last updated 30 July 2026, returns 66,161 reports naming OZEMPIC. Of those, 32,483 carry a serious flag and 33,650 do not.<\/p>\n The most reported term is nausea at 9,751 reports. Then off label use at 6,949, vomiting at 6,341, diarrhea at 5,980, decreased appetite at 4,507, constipation at 4,406 and weight decreased at 4,157. Eighth on the list, at 3,431 reports, sits impaired gastric emptying.<\/p>\n Impaired gastric emptying outranks headache, which logs 2,811. The condition the label treats as a warning is a thing patients volunteer in writing, more often than they mention the headache most people shrug at.<\/p>\n The same archive holds 1,536 reports naming pancreatitis, 645 for ileus and 604 for optic ischaemic neuropathy.<\/p>\n Here is the honesty this page needs. FAERS is a voluntary reporting system with no denominator, no verification and no control group. It cannot compute a rate, and a report is not proof of cause. Nothing in those 66,161 rows tells you how likely any outcome is. The archive shows what people experienced badly enough to file, and the gap between the label’s tidy percentage and that pile of filings is the gap between a trial and a pharmacy queue.<\/p>\n The label answers one small version of the restart question. A missed dose can be taken within five days. Past five days, the dose is skipped and the weekly schedule continues. That rule covers a week of ordinary life, not several months away from the drug.<\/p>\n Nothing in the prescribing information addresses a return at the top dose after a long gap, and the case report is explicit that the gap is where the injury began. The authors do not claim that reinitiation harms most people. One patient cannot establish frequency, and the paper does not pretend otherwise. Their recommendation: suspect esophageal complications in anyone with chest pain and vomiting around an initiation or reinitiation.<\/p>\n Any break longer than a couple of weeks is a question for the prescriber. A clinic that hands over a vial and a dose chart without asking about the gap has skipped the only avoidable part.<\/p>\n Semaglutide is one molecule and two products, and the two labels describe different populations. Ozempic holds three indications: type 2 diabetes, cardiovascular risk reduction in adults with type 2 diabetes and established cardiovascular disease, and kidney outcomes in adults with type 2 diabetes and chronic kidney disease.<\/p>\n Wegovy is the obesity product, dosed at 2.4 mg weekly, and its table is rougher. The Wegovy label reports nausea in 44% of adults at 2.4 mg against 16% on placebo, diarrhea in 30% and vomiting in 24%, as we set out in the Wegovy label numbers breakdown<\/a>. Anyone quoting Wegovy’s 44% at an Ozempic patient has mixed two documents.<\/p>\n A molecule is not a product. A product is not a dose.<\/p>\n Derington and colleagues published the largest available head to head comparison in JAMA Network Open<\/a> on 1 October 2025. They followed 21,790 veterans with type 2 diabetes who started liraglutide, semaglutide or dulaglutide between January 2018 and December 2021, with gastrointestinal outcomes tracked to 31 March 2023. Semaglutide accounted for 10,838 of them.<\/p>\n The only gastrointestinal difference the study found was a lower risk of gallstones and acute cholecystitis with dulaglutide against semaglutide, hazard ratios of 0.72 and 0.62. Gastroparesis, intestinal obstruction and acute pancreatitis showed no significant difference between the three drugs.<\/p>\n In the largest real world comparison on the shelf, the class looks fairly similar to itself. The variables that moved outcomes in the case report were dose, titration and a person deciding to skip the ramp. Those are the variables a patient controls with a prescriber in the room.<\/p>\n The label warns about it without quoting a rate for the diagnosis. Section 5.7 covers severe gastrointestinal reactions and states that Ozempic is not recommended in patients with severe gastroparesis. Severe reactions ran 0.8% at 1 mg against 0% on placebo. In 3,431 of 66,161 FDA reports naming Ozempic, the reporter used the term impaired gastric emptying. Reporting counts are not incidence rates.<\/p>\n The label states that most nausea, vomiting and diarrhea reports arrived during dose escalation, and the pooled trials ran a mean of 32.9 weeks. No source states an average duration in weeks, so this page will not invent one. Persistent vomiting or chest pain is a reason to seek care, not a reason to wait out a schedule.<\/p>\n The label covers only the small version: a missed dose inside five days can be taken, past five days it is skipped and the weekly schedule resumes. A break of months sits outside that rule. The published case involved a restart at 2.4 mg weekly after months off, with no titration, and a ruptured esophagus the next day. That decision belongs to a prescriber.<\/p>\n No. The approved indications are type 2 diabetes, cardiovascular risk reduction in type 2 diabetes with established cardiovascular disease, and kidney outcomes in type 2 diabetes with chronic kidney disease. Weight reduction is the Wegovy indication. Among 66,161 reports naming Ozempic, 6,949 list off label use and 3,294 list product use in unapproved indication.<\/p>\n The label says the human answer is unknown, and it says so in a boxed warning. Semaglutide caused thyroid C cell tumors in rodents, and the label states that human relevance has not been determined. Ozempic is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. The archive holds 23 reports naming thyroid neoplasm, too few to prove anything and too vague to reassure.<\/p>\n No. Compounded semaglutide is not FDA approved, and it is not the product tested in the trials behind these percentages. A clinic selling it cannot borrow Ozempic’s label as its own evidence.<\/p>\n Each figure above describes a trial population that entered at 0.25 mg, climbed on a ladder, and had investigators counting what happened next. The esophagus in Grand Rapids belonged to a woman who did none of that, because the ladder mattered and no one told her so on the way back in.<\/p>\n Labels describe the trial. Patients live in the gap.<\/p>\n Sources: DailyMed, OZEMPIC prescribing information, version 20, effective 1 June 2026<\/a>, openFDA Drug Adverse Event API, data last updated 30 July 2026, queried 17 October 2026<\/a>, Journal of Cardiothoracic Surgery, Boerhaave’s syndrome associated with GLP-1 receptor agonist use, 12 June 2026, PMID 42286576<\/a>, JAMA Network Open, Liraglutide vs Semaglutide vs Dulaglutide in Veterans With Type 2 Diabetes, 1 October 2025, PMID 41082229<\/a>.<\/p>\nOzempic Side Effects in the Label – The Warning Novo Rewrote in October 2025<\/h2>\n
66,161 Reports – What the FDA’s Public Archive Shows and What It Cannot Prove<\/h2>\n
Reinitiation – The Risk the Search Results Skip<\/h2>\n
Ozempic Side Effects vs Wegovy Side Effects – Same Molecule, Two Labels<\/h2>\n
The 21,790 Patient VA Study – A Check on the Panic<\/h2>\n
Frequently asked questions<\/h2>\n
Does Ozempic cause gastroparesis?<\/h3>\n
How long do Ozempic side effects last?<\/h3>\n
Can I restart Ozempic at the same dose after a break?<\/h3>\n
Is Ozempic approved for weight loss?<\/h3>\n
Does Ozempic cause thyroid cancer?<\/h3>\n
Is compounded semaglutide the same as Ozempic?<\/h3>\n
The part the percentages leave out<\/h2>\n